Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

Blood

Volumn 100, Issue 13, 2002, Pages 4351-4357

  Tsimberidou, Apostolia M ^a   McLaughlin, Peter ^a   Younes, Anas ^a   Rodriguez, Maria A ^a   Hagemeister, Fredrick B ^a   Sarris, Andreas ^a   Romaguera, Jorge ^a   Hess, Mark ^a   Smith, Terry L ^a   Yang, Ying ^a   Ayala, Ana ^a   Preti, Alejandro ^a   Lee, Ming Sheng ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERFERON; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LIVER TOXICITY; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0037114752     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0269     Document Type: Article

References (42)

1. Horning S. Natural history of and therapy for the indolent non-Hodgkin's lymphoma. Semin Oncol. 1993;20:75-88.
2. Velasquez WS, Cabanillas F, Salvador P, et al. Effective savage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117-122.
3. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol. 1994;12:1169-1176.
4. Coltman CA, McDaniel TM, Balcerzak SP, Morrison FS, Von Hoff DD. Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. Invest New Drugs. 1983;1:65-70.
5. Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O'Connell MJ. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol. 1985;3:769-775.
6. McLaughlin P, Hagemeister FB, Swan F, et al. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol. 1994;5(suppl 2):73-77.
7. Gribben JG, Freedman AS, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment., Blood. 1991;78:3275-3280.
8. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood. 1993;81:3449-3457.
9. McLaughlin P, Hagemeister FB, Swan F, et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994;12:575-579.
10. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethaxone: An effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
11. McLaughlin P, Cabanillas F, Hagemeister FB, et al. CHOP-Bleo plus interferon for stage IV lowgrade lymphoma. Ann Oncol, 1993;4:205-211.
12. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's lymphoma pathologic classification project. Cancer. 1982;49:2112-2135.
13. Pugh WC. Is the working formulation adequate for the classification of the low grade lymphomas? Leuk Lymphoma. 1993;10:1-8.
14. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Ann Oncol. 1999;10:1419-1432.
15. Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. Blood. 1977;49:325-333.
16. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science. 1987;237:175-178.
17. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
19. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987;5:1670-1672.
20. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998;91:2955-2960.
21. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-719.
22. Kaplan FL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
24. Romaguera JE, McLaughlin P, North L, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol. 1991;9:762-769.
25. Shipp MA, Harrington DP, Anderson JR, et al. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
26. Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996;14:514-519.
27. Coiffier B, Neidhardt-Berard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study. Ann Oncol. 1999;10:1191-1197.
28. Emmanouilides C, Rosen P, Rasti S, Territo M, Kunkel L. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial. Hematol Oncol. 1998;16:107-116.
29. Crawley CR, Foran JM, Gupta RK, et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone, and dexamethasone in patients with follicular lymphoma. Ann Oncol. 2000;11:861-865.
30. Foussard C, Deconninck E, Desablens B, et al. Improved response after fludarabine, mitoxantrone in first line treatment of patients with advanced low-grade non-Hodgkin's lymphoma [abstract]. Proc Am Soc Clin Oncol. 2001;20:280a.
31. Zinzani PL. A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma [abstract]. Blood. 2001;98:842a.
32. Velasquez W, Lew D, Miller T, Fisher R. SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone in untreated advanced low grade lymphoma: An effective, well tolerated regimen [abstract]. Proc Am Soc Clin Oncol. 1999;18:9a.
33. Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up: A report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;18:987-994.
34. O'Brien S, Kantarjian HM, Cortes J, et al. Results of fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
35. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
36. Gregory S, Vose J, Modiano M, et al. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantronecontaining regimen. Leuk Lymphoma. 2001;40:315-324.
37. Hochster H, Weller E, Kuzel T, Frankel S, Horning S. Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496, an ECOG and CALGB study [abstract]. Proc Am Soc Clin Oncol. 2002;21:282a.
38. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol. 2000;11(suppl 1):S137-S140.
39. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al. Clearing of cells bearing the bcl-2 t(14;18) translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol. 2001;12:109-114.
40. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood. 2001;97:101-106.
41. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93:3081-3087.
42. Montoto S, Lopez-Guillermo A, Colomer D, et al. Bcl-2 rearrangement sites in follicular lymphoma: Correlation with clinical features and outcome [abstract]. Hematol J. 2000;1(suppl 1):180.